Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. operates as a US-based biopharmaceutical company. Founded in 1993, it is headquartered in Cambridge, Massachusetts.
Overview
Strengths
- EV/EBITDA (-91.59) is lower than the sector mean (85.60).
- EV/EBIT (-97.44) is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -98.39%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (2.21) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (-7.75%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | -91.6 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -7.8% |
| Net Debt/EBITDA | 2.2 |